| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Arcus Biosciences, Inc. | Director | Common Stock | 25,300 | $444 K | $17.55 | Jun 6, 2024 | Direct |
| ACELYRIN, Inc. | Director | Common Stock | 14,675 | $109 K | $7.41 | Oct 4, 2023 | Indirect |
| ACELYRIN, Inc. | Director | Director Stock Option (right to buy) | 92,158 | Jun 7, 2024 | Direct | ||
| CHIMERIX INC | Director | Stock Option (Right to Buy) | 60,000 | Jun 9, 2023 | Direct | ||
| ALUMIS INC. | Director | Stock Option (Right to Buy) | 38,000 | Jul 1, 2024 | Direct | ||
| Arcus Biosciences, Inc. | Director | Stock Option (Right to Buy) | 24,000 | Jun 6, 2024 | Direct | ||
| Xenon Pharmaceuticals Inc. | Director | Stock Option (Right to Buy) | 15,542 | Jun 5, 2024 | Direct | ||
| Adverum Biotechnologies, Inc. | Director | Stock Option (Right to Buy) | 3,300 | Jun 17, 2024 | Direct | ||
| Turning Point Therapeutics, Inc. | Director | Stock Option (right to buy) | 0 | Aug 17, 2022 | Direct |